相关实验视频
Updated: Jul 14, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
从天然胰岛素到设计模拟剂:化学生物学探索
Yanxian Zhang1, Danny Hung-Chieh Chou1
1Division of Endocrinology and Diabetes, Department of Pediatrics, School of Medicine, Stanford University, 1701 Page Mill Road, Palo Alto, CA 94304, USA.
Chembiochem : a European journal of chemical biology
|October 6, 2023
概括
化学生物学推动了胰岛素研究,使改进的治疗方法成为可能,并推动了对葡萄糖敏感胰岛素的创新. 这一领域继续塑造未来的胰岛素开发和应用.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 化学生物学 化学生物学
背景情况:
- 1921年胰岛素的发现标志着医学科学的重要里程碑.
- 了解胰岛素的结构和功能的进步导致了治疗方面的进步.
- 最近的创新涉及修改胰岛素治疗的蛋白质工程.
研究的目的:
- 突出化学生物学在胰岛素研究中的作用.
- 讨论胰岛素修饰和治疗开发方面的创新.
- 为了探索葡萄糖敏感胰岛素的未来.
主要方法:
- 关于胰岛素研究和化学生物学的科学文献的综述.
- 分析胰岛素修饰的蛋白质工程技术.
- 讨论开发量身定制胰岛素疗法的进展.
主要成果:
- 化学生物学在推动胰岛素研究创新的过程中发挥了关键作用.
- 蛋白质工程使得开发具有特定药理特征的胰岛素成为可能.
- 追求自我调节的,对葡萄糖有反应的胰岛素是一个持续的主要目标.
结论:
- 化学生物学对于推进胰岛素疗法至关重要.
- 未来的胰岛素研究很可能会专注于复杂的修改和对葡萄糖敏感的系统.
- 化学生物学领域的持续创新有望进一步彻底改变胰岛素治疗.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
407
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
407
Glucagon-like Receptor Agonists
337
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
337
Drug Discovery: Overview
8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
Structure-Activity Relationships and Drug Design
742
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
742
Insulin Formulations: Types and Delivery
209
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
209
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K

